Drug Profile
Research programme: small molecule therapeutics - Apexian Pharmaceuticals
Alternative Names: APE/Ref-1 inhibitors - Apexian Pharmaceuticals; APX-2048; APX-2050Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator ApeX Therapeutics; Indiana University School of Medicine
- Developer Apexian Pharmaceuticals; Ocuphire Pharma
- Class Small molecules
- Mechanism of Action Protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Eye disorders; Macular degeneration; Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for preclinical development in Macular-degeneration in USA (Intravitreous)
- 28 Feb 2024 No recent reports of development identified for research development in Eye-disorders in USA (Parenteral)
- 16 Nov 2020 Ocuphire Pharma receives grant from the National Eye Institute (NEI) of the National Institutes of Health for APX 2009 and APX 2014 development in Diabetic retinopathy and Diabetic macular oedema